Evaluation of Methods for the Determination of Chromogranin A in Routine Blood Samples

• Status: Completed
• Trial end date: 2012-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this study is to compare several methods for measurement of Chromogranin A in their ability to serve as a marker for disease activity in patients with neuroendocrine tumors.

Further, in a subgroup, we will determine if taking a proton pump inhibitor affects Chromogranin A levels.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Western Ontario, Canada
• Treatments: Dexlansoprazole; Lansoprazole

Criteria

Patients:

Inclusion Criteria:

• having neuro-endocrine disease

Exclusion Criteria:

• age below 18 or above 70 years

• prostate cancer

• kidney failure (estimated GF < 30 mL/Min)

• heart failure

• chronic atrophic gastritis

• pregnancy

Healthy subjects:

Inclusion Criteria:

• healthy

Exclusion Criteria:

• age below 18 or above 70 years

• taking any chronic medication (except OCP)

• prostate cancer

• kidney failure (estimated GFR < 30 mL/min)

• heart failure

• pheochromocytoma

• islet cell tumors

• medullary thyroid cancer

• essential hypertension

• neurofibromatosis

• use of proton pump inhibitors

• chronic atrophic gastritis

• pregnancy